Preclinical pharmacology of a lipophenol in a mouse model of light-induced retinopathy

Nicolas Taveau1,2, Aurélie Cubizolle1,2, Laurent Guillou1,2, Nicolas Pinquier1, Espérance Moine3, David Cia4, Vasiliki Kalatzis1,2, Joseph Vercauteren3, Thierry Durand3, Céline Crauste3 and Philippe Brabet1,2

Abstract
Environmental light has deleterious effects on the outer retina in human retinopathies, such as ABCA4-related Stargardt’s disease and dry age-related macular degeneration. These effects involve carbonyl and oxidative stress, which contribute to retinal cell death and vision loss. Here, we used an albino Abca4−/− mouse model, the outer retina of which shows susceptibility to acute photodamage, to test the protective efficacy of a new polyunsaturated fatty acid lipophenol derivative. Anatomical and functional analyses demonstrated that a single intravenous injection of isopropyl-phloroglucinol-DHA, termed IP-DHA, dose-dependently decreased light-induced photoreceptor degeneration and preserved visual sensitivity. This protective effect persisted for 3 months. IP-DHA did not affect the kinetics of the visual cycle in vivo or the activity of the RPE65 isomerase in vitro. Moreover, IP-DHA administered by oral gavage showed significant protection of photoreceptors against acute light damage. In conclusion, short-term tests in Abca4-deficient mice, following single-dose administration and light exposure, identify IP-DHA as a therapeutic agent for the prevention of retinal degeneration.

Introduction
Light-induced retinal degeneration is a pathophysiological condition that affects both young and elderly people. The same molecular and cellular mechanisms are often involved. In all cases, toxic photoproducts arise from vitamin A metabolites (carbonyl stressors) and oxidative stress, both of which lead to the death of outer retina cells, i.e., the retinal pigment epithelium (RPE) and photoreceptors. In young patients with autosomal recessive Stargardt’s disease (STGD1), the most common juvenile macular dystrophy, and in elderly patients with advanced aged-related macular degeneration (AMD), high levels of photoreactive metabolites in the retina enhance light-induced susceptibility.

Photochemical mechanisms in the retina depend on oxygen concentration and photopigments. The high oxygen tension supplied from the dense vascular bed of the choroid exposes the outer retina to oxidation. Retinal photodamage is accompanied by lipid peroxidation, suggesting that this photodamage is mediated by reactive oxygen species (ROS). Oxidative stress appears to be an early event in the retinal light damage process. There are several chromophores that absorb visible light in the outer retina, and their potential involvement in retinal photodamage was previously discussed. Studies report that rhodopsin (the visual pigment) plays a critical role in photodamage. Rather, the bleaching products of rhodopsin have been suggested to be photodamage mediators.

All-trans-retinal (atRAL) is one of the products of rhodopsin photobleaching, a toxic aldehyde and a potent photosensitizer. atRAL forms in the photoreceptor outer segments (POS) by rhodopsin bleaching as the result of
the photoisomerization of 11-cis-retinal (11cRAL), the visual pigment chromophore linked to opsin by Schiff base reaction\(^\text{10}\) (Scheme 1). Hydrolysis then releases aRAL from the opsin protein, aRAL which then transiently accumulates in the inner leaflet of the POS disc membranes\(^\text{11}\). The accumulation of free aRAL can impose a risk of phototoxic damage to the retina induced by visible light\(^\text{9}\). The photodegradation of aRAL can generate singlet oxygen and superoxide, which cause oxidative damage to cellular components.

Alternatively, the free aRAL in the outer segments of the photoreceptors may react by condensation with phosphatidylethanolamine (PE) to form N-Retinylidene PE (NRetPE) (Scheme 1). ABCR is a flavinase that facilitates NRetPE hydrolysis and aRAL release\(^\text{12}\), which is then reduced to all-trans-retinol (aRAL) by NADPH-dependent retinol dehydrogenases\(^\text{13}\). This reduction is the first limiting step of the visual (retinoid) cycle, a metabolic process that provides 11cRAL to regenerate visual pigments\(^\text{14}\). However, deficiency of ABCA4, as in the case of STGD1, strongly slows the clearance of aRAL in POS and increases susceptibility of the retina to photodamage\(^\text{15}\). Another effect induced by the accumulation of aRAL in POS is an increase in lipofuscin bis-retinoid pigments in the RPE\(^\text{16}\). The bis-retinoid A2PE, which arises from the condensation of two aRLs with PE, following phagocytosis by RPE, generates A2E, a blue light-sensitive chromophore (430–470 nm), found in lipofuscin and toxic to the RPE\(^\text{17}\).

Recent reports have shown that the sequestration of aRAL with primary amines or the inhibition of the visual cycle isomerase RPE65, the second limiting step of the 11cRAL regenerative process, can lower the aRAL concentration to safe levels and prevent retinal degeneration in mutant mice\(^\text{18,19}\). Drugs that sequester aRAL contribute to the prevention of light-induced damage\(^\text{20}\). The identification of new classes of sequestrating compounds would be relevant to future therapies for macular dystrophies\(^\text{21}\). Previously, we described the protective effect of a docosahexaenoic acid (DHA) lipophenol conjugate, IP-DHA, on ARPE-19 cells challenged with a toxic concentration of aRAL\(^\text{22}\). More recently, we reported that IP-DHA can reduce the toxicity of aRAL by acting either as an aRAL or ROS scavenger or as an Nrf2-mediated enzyme defense inducer\(^\text{23}\), which mediates the transcription of antioxidant/cytoprotective genes\(^\text{24}\).

Here, we studied the therapeutic effects of IP-DHA on acute retinopathy using the Abca4 knockout (Abca4\(^{-/-}\)) mouse model. We demonstrate that a single intravenous injection of IP-DHA reduced the photoreceptor loss induced by light exposure and preserved visual function over time. Furthermore, IP-DHA did not affect the
retinoid visual cycle. Moreover, IP-DHA administered by oral gavage using a nonoptimized formulation showed significant protection of photoreceptors.

**Materials and methods**

**Chemicals**

IP-DHA was synthesized and purified as previously described\(^2\). IP-DHA-atRAL adducts were synthesized from isopropyl-phloroglucinol, as described in the supplemental material. DHA ethyl ester, generously gifted by Vincent Rioux (Agrocampus Ouest, Rennes, France), was purified using an n-3 polyunsaturated fatty acid (PUFA) marine oil (Omegavie 4020EE Qualitlysilver, Polaris) process, as described\(^2\). Emixustat hydrochloride was purchased from Ambinter (Amb24183355, GreenPharma Orleans). Fatty acid-free bovine serum albumin (BSA) was purchased from Sigma-Aldrich (# A8806). AtRAL and all-trans-retinyl palmitate (atRPalm) standards were purchased from Sigma-Aldrich (# R2500 and R3375, respectively), whereas 11cRAL was generously gifted by Rosalie Crouch (University of South Carolina, SC, USA). DPBS (1 X from Gibco, ref 14190–094) was the dilution buffer. Tropicamide (Mydriaticum 0.5% eye drops, Thea) was used to dilate the pupils, and ketamine (Imalgene 1000, Merial), xylasine (Rompun 2%, Bayer Healthcare), and cebesine (0.4% eye drops, Bausch and Lomb) were used to anesthetize the mice.

**Abca4 knockout mice**

Albino Abca4\(^{+/−}\) mice, bred from a mixed 129/S5 \times C57BL/6-Tyr\(^{−/−}\)-brd background, were purchased from Taconic Biosciences Inc. Mice were reared and genotyped for the Abca4 null mutation and were homozygous for Rpe65-Leu450. The lack of expression of the ABCR protein in the retina of Abca4\(^{+/−}\) mice was confirmed by western blot analysis (Anti-ABCA4 antibody [3F4], Novus Biologicals NBP1-30032, 1/1000; K. Damodar, personal communication). The rd8 mutant was absent in this Abca4\(^{−/−}\) line. Mice were subjected to standard 12-h light (90 lux) and 12-h dark cycles at a room temperature of ~22 °C and fed a standard rodent diet (SAFE 04) without DHA ad libitum. The mice were housed in facilities accredited by the French Ministry of Agriculture and Forestry (no C34-17236 – 19 December 2014). The care and use of animals was performed according to the European Directive 2010/63/EU, and the experimental procedures were approved by the French Ministry of National Education and Research (APAFIS #151117-2018051712092842v3).

**IP-DHA administration**

Mice between 9 and 12 weeks of age, of both sexes, were weighed to adjust the quantity of administered compound.

For intravenous injection, the mice were divided into untreated, BSA-treated, and treated groups with IP-DHA at doses ranging from 5 to 30 mg/kg. IP-DHA was dissolved in absolute ethanol (0.1 mg/µl); the volume required for one dose of IP-DHA was mixed in sterile PBS with 0.175 g/ml lipid-free BSA in a molar ratio of 1/1–5/1 (IP-DHA/BSA). This mixture was vortexed for 2 min and incubated at 37 °C for 2 h. We assumed that IP-DHA behaves like DHA by forming complexes with BSA at the appropriate concentrations, as previously described\(^2\), and 100 µl was injected into the tail vein 5–10 min before exposure to light.

For oral administration, the mice were orally gavaged with a 22-gauge needle containing 100 µl of soybean oil as a control vehicle (SIO, 62053 St-Laurent-Blangy, France); emixustat (40 mg/kg) suspended in DMSO, replenished in soybean oil and containing less than 10% (v/v) DMSO; IP-DHA or DHA-ethyl ester (between 40 and 150 mg/kg) directly suspended in soybean oil.

**Light-induced retinal degeneration**

After the mice were dark adapted (DA) for 24–48 h, their pupils were dilated with 0.5% tropicamide. The mice were injected with the IP-DHA/BSA complex in the dark, and then exposed to constant light (2 cool white fluorescent lamps, OSRAM of 26 watts, 1800 lm, maximum photopic efficiency of ~470 nm, light intensity averaged 24 mW/cm\(^2\) corresponding to ~20.000 lux) for 2 h in a white plastic bucket with a fan. Mice were kept in the dark for 5 days before we performed final retinal evaluations. Throughout the experiment, the ambient temperature was 22 °C, identical to that of the breeding box, to avoid an increase in body temperature, which could further damage the retina\(^5\).

**Histological analysis**

All animals were killed by cervical dislocation. The eyes were rapidly enucleated and fixed in 4% paraformaldehyde for 24 h at 4 °C. Eye cups were embedded in paraffin and cut into 5 µm sagittal sections. For hematoxylin/eosin/saffron (HES) staining, the sections were deparaffined, labeled with HES using standard protocols, rinsed and mounted in Moeviol.

**Spectral-domain optical coherence tomodraphy (SD-OCT)**

Spectral-domain optical coherence tomography (SD-OCT) was performed separately on each eye using an Envisu R2000 SD-OCT device (Bioptigen, Durham, NC). The pupils were dilated by applying 0.5% tropicamide to the cornea. The mice were anesthetized by an intraperitoneal injection of a mixture of ketamine (70 mg/kg) and xylazine (14 mg/kg), and local anesthesia was performed with a drop of oxybuprocaine (0.4% cebesine) on the cornea. Corneal hydration was maintained with Systane Ultra (Alcon, Fort Worth, TX) lubricant eye drops. Animal preparation and image acquisition were performed as...
previously described. Analyses were performed using a rectangular scanning protocol (1.4 mm × 1.4 mm with 1000 A-scans per B-scan × 100 B-scans) while centered on the optic nerve. The thickness of the inner nuclear layer (INL), outer nuclear layer (ONL), and photoreceptor segments (PS = IS + OS) was measured and expressed in arbitrary units using ImageJ software. Twenty measurements were performed per analysis and averaged for both eyes.

Electroretinography
All electrophysiological examinations were conducted using the Visiosystem (SIEM, France). Animals were prepared and anesthetized, and electroretinogram recording (binocular full-field ERG) was performed with cotton electrodes, as previously described.

Retinoid analysis
The mice were killed by cervical dislocation before the eyes were rapidly enucleated, frozen in liquid nitrogen, and stored at −80 °C until use. Retinoids were extracted from eyes as described and quantified from the peak areas using calibration curves determined with established standards. An A2E assay was performed on six eyes per genotype (wild type or Abca4−/−). Eyes were homogenized in 500 μl of absolute ethanol and centrifuged, and ethanol extracts were concentrated using a SpeedVac AES1000 (Savant Instruments, Saroo Nagar). The residual volume (~20 μl) was analyzed by reverse-phase HPLC. The absorbance of A2E and iso-A2E was measured at 430 nm, and A2E was quantified from the peak area using a calibration curve determined with synthetic A2E.

Statistics
Statistical analyses were performed using Graph Pad Prism 5.0 software. The data of two samples were first analyzed with the Shapiro–Wilk normality test, and then two-tailed p-values were determined using either an unpaired Student’s t test or a nonparametric Mann–Whitney test. One-way ANOVA was used to compare more than two samples. Bonferroni’s or Dunn’s multicomparison adjustment was used as the post hoc test to calculate the significance levels. A p-value of < 0.05 was considered significant. The linear correlation was measured by Pearson’s r correlation coefficient.

Results

The light-induced retinal damage paradigm
The albino Abca4−/− mice, an animal model of Stargardt’s disease, used herein had a atRAL level similar to that of wild-type mice in adulthood (6–7 months) but had significantly lower 11cRAL levels and accumulated A2E faster, according to a recent report (Supplementary Fig. S1a, S1b). However, there was no photoreceptor degeneration in the mice before 10 months of age (Supplementary Fig. S1c), suggesting that the level of A2E accumulation was too low to induce toxicity or that it was well tolerated in the outer retina. Therefore, to test the protective effect of IP-DHA on photoreceptors, we used a paradigm of acute retinal damage induced by light in mice aged 9–12 weeks (see Material and methods section). These mice were reared in darkness for 24–48 h, an appropriate amount of time for regenerating the visual pigment (opsin + 11cRAL), and then exposed to bright light. The overproduction and photooxidation of atRAL caused by intense light illumination and the genetic defect in the Abca4 gene can induce delayed photoreceptor degeneration, which was quantified after 5 days in the dark by retinal histological analysis (Fig. 1). Light exposure for 2 h produced a reduction in the thickness of the photoreceptor ONL, which was 58.0 ± 0.2% of that of mice not exposed to light. Exposure for 1 h caused only a 10.0 ± 0.4% reduction. The ONL/INL ratio represents the OCT results with the thickness of the INL used as an internal standard as it does not significantly change after light exposure. All protective assessments were therefore conducted after a 2-h light exposure.

IP-DHA treatment prevents light-induced acute retinal degeneration
IP-DHA is an oily compound that is poorly soluble in water because of its long PUFA chain (DHA). To test its effect on acute light-induced damage, IP-DHA was complexed to defatted BSA and administered in the dark by intravenous injection in the tail vein as a single dose (5–30 mg/kg) prior to light exposure. Five days post-light exposure, the mice were evaluated by in vivo retinal imaging by histological analysis (Fig. 2), spectral-domain optical coherence tomography (SD-OCT, Fig. 3), and full-field electroretinography (ERG, Fig. 4). Whereas BSA injection did not prevent retinal degeneration and induced an average loss of photoreceptors comparable to no injection (57.9 ± 6.8% and 56.4 ± 2.5%, respectively, BSA vs NI, Fig. 2b), IP-DHA prevented light-induced acute degeneration and enabled the recovery of 80–85% of intact photoreceptors in a dose-dependent manner (Figs. 2b and 3b). IP-DHA injection markedly rescued the b-wave and a-wave amplitudes (Fig. 4a, b). A strong correlation between anatomical (ONL/INL) and functional (ERG) measurements suggested that the conservation of light-detecting photoreceptor cells was the cause of visual sensitivity rescue (Fig. S2). The level of 11cRAL was also well correlated with the a-wave amplitude, making 11cRAL a biomarker of photoreceptor status. The rescue of photoreceptor function (a-wave amplitude) lasted for at least 3 months postinjection (Fig. 5). By contrast, the visual function of untreated and BSA-treated mice was unchanged, indicating a permanent deficit that
lasted more than 3 months after light exposure. During these 3 months, the mice showed normal weight gains and were generally indistinguishable from each other. Overall, this posttreatment follow-up does not suggest any adverse dose-related effects. Collectively, these results emphasize the efficacy of IP-DHA in preventing acute retinal damage.
and support the protective effect of therapy with this compound.

**Protection in mice does not affect the retinoid cycle**

We asked whether IP-DHA might react in vivo with aRAL and impair chromophore regeneration. By exposing the mice to bright light for 2 min, aRAL reached maximum levels prior to its reduction (Supplementary Fig. S3a). We then returned the mice to the dark for several hours before HPLC analysis of retinoid levels (Figs. S3b and 6). Chromophore 11cRAL levels decreased by ~90% after bleaching and then regenerated within the first hour of dark adaptation, whereas arRPalm accumulated postbleaching and did not return to baseline levels until 24 h postadaptation (Fig. 6a, b). By contrast, aRAL increased after bleaching and declined rapidly to basal levels after 1 h of dark adaptation (Fig. 6c). IP-DHA tended to reduce aRAL in the dark before and after bleaching, but this effect was not significant. We conclude that IP-DHA might partially reduce aRAL without affecting the retinoid cycle.

**Comparative effects of IP-DHA and emixustat by oral pretreatment**

A comparison of IP-DHA with emixustat (EMX), well known to have protective effects against acute light-induced retinal degeneration 19, showed that these treatments had similar effects (Fig. 7). Both compounds generated higher a-wave amplitudes in the rod and cone ERG responses than did the oil vehicle (p < 0.001). EMX treatment (40 mg/kg) by oral gavage 24 h before light exposure protected more than 90% of the photoreceptor response, which was not significantly different from the photoreceptor response of unexposed mice (DA). IP-DHA showed a dose-dependent effect after 6 h of pretreatment, protecting up to 70% of the photoreceptor ERG response at the highest dose (150 mg/kg). Thus, even in the absence of an optimized oral formulation, IP-DHA had a protective effect against light-induced retinal degeneration, which was promising. Remarkably, DHA ethyl ester (Et-ODHA, 150 mg/kg) had no protective effect, suggesting that simple DHA supplementation is not sufficient to provide photoreceptor protection and thus that the isopropyl-phloroglucinol moiety is a necessary part of the lipophenol structure to observe IP-DHA activity.

**Effect of emixustat and IP-DHA on RPE65 isomerase**

EMX is a visual cycle modulator that inhibits the RPE65 isomerase of the visual cycle, slows the regeneration of 11cRAL and thus limits the rate of aRAL produced by light 34. A first explanation for the difference in the protective efficacies of EMX and IP-DHA may be the inhibition of RPE65. We thus tested whether we could reproduce the inhibitory effect of EMX in HEK cells expressing LRAT and RPE65 (HEK-LR) and compared the inhibitory effect of EMX to that of IP-DHA in this model. HEK-LR cells were incubated initially with 40 µM EMX or with 40–80 µM IP-DHA for 24 h and then with 10 µM vitamin A for an additional 24 h. Retinoids were
extracted from cell lysates and analyzed by normal-phase HPLC. As shown in Fig. 8, neither IP-DHA nor EMX affected the production of Δ9Palm catalyzed by LRAT, and only EMX significantly inhibited the formation of 11cROL catalyzed by RPE65. Therefore, our data show that IP-DHA does not affect RPE65 isomerase in vitro, unlike EMX.

**Discussion**

In the present study, we evaluated the therapeutic efficacy of a new small molecule, a phloroglucinol derivative, referred to as lipophenol (or phenolipid). The isopropyl function of this molecule reinforces the nucleophilic nature of its aromatic ring, and DHA should improve its bioavailability and its capacity to reach the outer retina. Our previous in vitro evaluation of cultured retinal cells has shown that this lipophenol reduces the toxicity of Δ9RAL (anti-carbonyl stress activity) and activates redox enzymes to promote antioxidant defenses23. We continued this preclinical evaluation with an in vivo study in mice using a light-induced photoreceptor degeneration model in the context of an Abca4 gene deletion that mimics human STGD1. Here, we will discuss the relevance of the mouse model as well as the structure-function relationship of lipophenol, its mode of action, and its comparison with small molecules already used in the treatment of macular degeneration.
Acute light-induced retinal degeneration in Abca4<sup>−/−</sup> mice

First, we examined the retinoid composition of the eyes of adult Abca4<sup>−/−</sup> mice (Supplemental Fig. S1a). These mice showed no accumulation of a<sub>R</sub>AL when subjected to standard light cycles, a result consistent with the recent report by Adler and colleagues. By contrast, 11cRAL levels were lower in Abca4<sup>−/−</sup> mice than in wild-type mice, suggesting the slower regeneration of chromophores. An explanation of this finding is that A2E accumulates faster over time in the Abca4<sup>−/−</sup> RPE than in the wild-type RPE (Supplemental Fig. S1b), a process that involves a delay in the removal of a<sub>R</sub>AL and its condensation with PE, rather than its entry into the visual retinoid cycle to regenerate 11cRAL. Moiseyev et al. described that A2E inhibits the regeneration of 11cRAL by binding to the RPE65 isomerase. Therefore, the lower rate of 11cRAL production is probably due to a defect in the two limiting steps of the visual cycle, consecutively, the reduction of atRAL to atROL facilitated by ABCR at the POS and the trans-cis isomerization of retinol catalyzed by RPE65 in the RPE. As we did not observe a significant decrease in scotopic photosensitivity before 10 months of age (Supplemental Fig. S1c), which corresponds to the OCT measurements reported previously; younger Abca4<sup>−/−</sup> mice do not exhibit retinal degeneration without exposure to intense light. This observation highlights the difference between the late onset of Abca4-related retinal degeneration in mice and the early adolescent onset of macular degeneration in humans. This difference is related to human retinal features, such as the presence of a macula and a much lower photoreceptor cell density. Limitation of the mouse model that can be overcome experimentally by exposure to light. Moreover, in patients with foveal sparing, vision loss was not noticed until adulthood, a clinical characteristic that, in association with lipofuscin accumulation, may be similar to the mouse phenotype.

We also demonstrated here that the acute form of light-induced retinal degeneration in Abca4<sup>−/−</sup> mice provides a good opportunity to reconstruct the temporal sequence of events leading to cell death. A prevalent finding, observed by SD-OCT imaging, was hyperreflectivity in the ONL at the earliest stages of retinal damage (up to 1 day postbleaching) without thinning of the retinal outer layer (Supplemental Fig. S4). Recently, hyperreflectivity in the outer nuclear layer of Stargardt patients was documented by OCT. The authors suggested that hyperreflectivity is the result of pathological alteration of the ONL, mainly in the cones. In this study, bright light damaged both the rods and cones of Abca4<sup>−/−</sup> mice (Supplementary Fig. S5). In the genetic context of Abca4 deficiency, light-induced retinal lesions appear to be an accelerated pathophysiological condition, which best represents STGD1 disease in mice.

Potency of lipophenol IP-DHA to protect photoreceptors from light-induced damage

Polyphenols have long been recognized as antioxidants; more recently, some of them have been shown to have anti-carbonyl stress activities, and their application in the treatment of neurodegenerative diseases has been widely highlighted in the past few years. Among polyphenols,
phloroglucinol is a monomer of phlorotannin with anti-carbonyl and oxidative stress (anti-COS) activities, which also displays therapeutic potential for neurodegenerative diseases. We previously reported the in vitro protective effects of phloroglucinol in outer retinal cells by reducing oxidative status and trapping a tRAL. However, a major disadvantage of phloroglucinol is its low bioavailability in the retina (unpublished data). Our strategy to improve selectivity for the retina relied on chemical modifications of the polyphenol core, leading to additional lipophilic derivatives. We synthesized phloroglucinol derivatives with DHA (omega-3, C22:6, n-3) linked on a phenolic functional group. The choice of DHA was dictated by (1) its high content in the photoreceptor disc membrane, the photoisomerization site that produces atRAL, and (2) several benefits in the retina that were previously described. The second modification performed on phloroglucinol was the introduction of an isopropyl functional group, whose electron-donating inductive effect should adjust the nucleophilicity of the aromatic ring to trap atRAL most efficiently.

With regard to these data, we evaluated the effect of IP-DHA on acute light-induced retinal degeneration in 9–12-week-old mice, which required only a 1-week experimental procedure. Similar experimental paradigms were extensively reported for testing the effects of small molecules on the development of acute light-induced retinal damage in mutant mice. We show that the use of IP-DHA as a therapeutic agent is very effective in protecting the outer retina of Abca4−/− mice from light-induced damage. This protective effect was dose-dependent and prevented both photoreceptor cell death and photosensitivity. The morphological (ONL/INL ratio in OCT and histological sections) and functional (a- and b-wave ERG) measurements were well correlated, suggesting a direct relationship between the number of surviving photoreceptors and the sensitivity of the retina to light stimulation. These changes also occur in the inner and outer segments of the photoreceptors, with a strong correlation of their lengths with the thickness of the nuclear layer and the light response (Supplemental Fig. S6). Together, these findings support that IP-DHA acts at the level of photoreceptor cells to maintain their integrity by preventing toxicity from the accumulation of free atRAL, which is produced by exposure to light in Abca4−/− mice.

**What is the mechanism of action of IP-DHA?**

A major question is the mechanism of action by which IP-DHA reduces the toxicity of atRAL. Phloroglucinol and isopropyl-phloroglucinol form irreversible chromene adducts with atRAL, suggesting that the isopropyl moiety can contribute to the reactivity of phloroglucinol. However, no adduct was identified or isolated under the same conditions by mixing IP-DHA and atRAL in test tubes. We chemically synthesized four potential adducts that could result from an IP-DHA reaction with atRAL. Phloroglucinol and isopropyl-phloroglucinol form irreversible chromene adducts with atRAL, which are produced by exposure to light in Abca4−/− mice.
structures) or by the low reactivity of IP-DHA with atRAL owing to the presence of DHA. We recently reported that several enzyme systems responsible for detoxifying ROS in the cell (antioxidant/electrophile response element (ARE/EpRE)-activated enzymes, regulated by the Nrf2/Keap1 pathway\textsuperscript{24}) are activated by IP-DHA\textsuperscript{23}. Now, we assume that the clearance of ROS is accomplished mainly through this mechanism. Among the enzymes activated by Nrf2 pathways, some enzymes target ROS but are also able to detoxify aldehyde derivatives, such as glutathione S-transferase, which also catalyzes the formation of the glutathione–aldehyde adduct (with HNE, for instance)\textsuperscript{51}. In addition, other enzyme systems could detoxify the retina, such as dehydrogenases. For example, ALDH1 and ALDH2 are described as enzymes involved in aldehyde detoxification\textsuperscript{51} and that use atRAL as a substrate\textsuperscript{52}. Overall, these data do not support the concept of the direct trapping of atRAL by IP-DHA in its lipophenolic form but rather a reduction in atRAL toxicity by acting on enzymatic cellular defenses capable of reducing carbonyl and oxidative stress. A final mode of action may be the release of phloroglucinol and the DHA moiety by enzymatic cleavage of lipophenol, both of which have a separate protective effect. However, no protective effect of DHA ethyl ester is shown here, suggesting that supplementation with DHA alone is not sufficient to ensure photoreceptor protection.
What benefit can lipophenol provide against STGD1 and dry AMD compared to other evaluated molecules?

Therapeutic agents target visual cycle inhibition and thereby reduce arRAL formation. Small molecules may slow down the visual cycle by reducing the amount of circulating vitamin A (fenchretinide and A1120 RBP4 antagonist) or by inhibiting the isomerase activity of RPE65 (isoretinoin, retinylamine, and EMX). ArRAL sequestrators (primary amines, VM-200, and EMX) and the tri-deuterated form of vitamin A (ALK-001) were able to slow the formation of bis-retinoids. The visual cycle modulator EMX is a primary amine that traps aldehyde in the photoreceptor, binds to and inhibits RPE65 in RPE. Recently, the most advanced oral treatment with EMX failed to reduce geographic atrophy in phase 2b/3 trials. The adverse events were likely related to the drug’s mechanism of action, RPE65 inhibition leading to decreased availability of 11-cis-retinal to the photoreceptors. New therapies that do not directly target visual cycle inhibition would be required to prevent severe adverse effects. Thus, the use of IP-DHA might be more beneficial than that of primary amines, as IP-DHA can act both on retinal toxicity and on the production of reactive carbonyl and oxygen species involved in the death of RPE and photoreceptors. The kinetics of chromophore regeneration after IP-DHA treatment revealed that IP-DHA does not impair the visual cycle. In addition, IP-DHA does not inhibit RPE65 isomerase; hence, it should not present side effects arising from this inhibitory outcome. Regarding toxicity, most primary amines are much more nucleophilic than the aromatic lipophenol; thus, they should present more potential toxicity than lipophenol. Furthermore, two natural components compose lipophenol: one polyphenolic moiety, an antioxidant compound present in foods, named phloroglucinol, an antispasmodic compound already approved by the FDA (Spasfon®), and DHA, a natural PUFA omega-3 present in food and beneficial for vision. We previously showed that the addition of isopropyl did not amend the low toxicity level of lipophenols. For all of these reasons, the risk of toxicity of lipophenols may be considered low. Validating this assumption, after a single injection, we observed no toxicity for over 3 months. However, to exclude all risks, future chronic treatment analyses should include toxicological studies.

In summary, based on the in vitro and in vivo biological activities of the main investigated molecule, IP-DHA, anti-COS lipophenols could represent a novel class of compounds that prevent retinal degeneration. Currently, several clinical trials on STGD1 are ongoing (https://www.clinicaltrials.gov/). Two molecules that act on the visual cycle are in clinical phase 2/3 development (ALK001, EMX). Concomitant nonpharmacologic approaches, such as stem cell (ClinicalTrials.gov NCT02445612) or gene delivery therapies (ClinicalTrials.gov NCT01736592), and pharmacologic treatments may be the key for efficient bitherapy. The therapeutic window for pharmacological treatment may be broader than that for other treatments if the compound shows preventive effects and is able to slow down the progression of the disease. Our approach is novel because lipophenols are able to target both carbonyl (arRAL) and oxidative stresses. This double reactivity represents a novel aspect of the therapeutic action of phenolic derivatives and addresses a challenge in the treatment of macular degeneration.

Acknowledgements

We would like to thank A-L. Bonnefont and M. Cen for their expertise in the IV injection of mice; C. Diez for assistance with the hyperreflectivity study; J. Bonnet for his technical assistance; the RHEM platform for the histologic preparation of paraffin sections; the INM facility for the management and maintenance of mice; and Montpellier RIO Imaging for the use of imaging tools. Fondation Stargardt, (2017-03) under the Aegis of Fondation Valentin Hauy, Retina France, ANR (ANR-18-CE18-0017-03), and SAT T AxlR (18/0093) funded this research. We thank Inserm, CNRS, and University of Montpellier for their support. We disclose grant support received from Fondation Stargardt and Agence National de la Recherche.

Author details

1Institut des Neurosciences de Montpellier, INSERM U1051, F-34091 Montpellier, France. 2Université de Montpellier, F-34091 Montpellier, France. 3Institut des Biomolécules Max Mousseron (IBMM), UMR 5247 - Université de Montpellier, CNRS, ENSCM, F-34095 Montpellier, France. 4Laboratoire de Biophysique Neurosensorielle, UMR INSERM 1107, Facultés de Médecine et de Pharmacie, F-63001 Clermont-Ferrand, France

Author contributions

Conceptualization and supervision: A.C., C.C., J.V., and P.B. Methodology, investigation, validation, and formal analysis: N.T., A.C., L.G., N.P., and E.M. Writing-original draft preparation: P.B. Writing-review and editing: D.C., E.M., T.D., C.C., and V.K. Funding acquisition: T.D., C.C., and P.B.

Conflict of interest

The authors declare that they have no conflict of interest.

Patent

Brabet, P., Gia, D., Guillon, L., Hamel, C., Vigor, C., Durand, T., Crauste, C., Vercauteren, J. New lipophenol compounds and uses thereof, WO2015162265A1 (2015).

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

accompanies this paper at https://doi.org/10.1038/s12276-020-0460-7.

Received: 18 February 2020 Revised: 18 April 2020 Accepted: 21 April 2020 Published online: 08 July 2020

References

1. Bellezza, I. Oxidative stress in age-related macular degeneration: Nrf2 as therapeutic target. Front. Pharmacol. 9, 1280 (2018).
2. Hunter, J. J. et al. The susceptibility of the retina to photochemical damage from visible light. Prog. Retin. Eye Res. 31, 28–42 (2012).
3. Liu, Y., Zhang, D., Wu, Y. & Ji, B. Docosahexaenoic acid aggravates phototoxic damage in retinal pigment epithelial cells via lipid peroxidation. J. Photochem. Photobiol. B 140, 85–93 (2014).
4. Boulton, M., Rozanowska, M. & Rozanowski, B. Retinal photodamage. J. Photochem. Photobiol. B 64, 144–161 (2001).
5. Noell, W. K., Walker, V. S., Kang, B. S. & Berman, S. Retinal damage by light in rats. Invest. Ophthalmol. 5, 450–473 (1966).
6. Grimm, C. et al. Protection of Rpe65-deficient mice identifies rhodopsin as a mediator of light-induced retinal degeneration. Nat. Genet. 25, 63–66 (2000).
7. van Norren, D. & Gorgels, T. G. The action spectrum of photochemical damage to the retina a review of monochromatic threshold data. Photochem. Photobiol. 87, 747–753 (2011).
8. Rozanowska, M. & Sama, T. Light-induced damage to the retina role of rhodopsin chromophore revisited. Photochem. Photobiol. 81, 1305–1330 (2005).
9. Rozanowska, M., Handzel, B., Boulton, M. E. & Rozanowska, B. Cytotoxicity of all-trans-retinal increases upon photodegradation. Photochem. Photobiol. 88, 1362–1372 (2012).
10. von Linig, J., Kiser, P. D., Golczak, M. & Palczewski, K. The biochemical and structural basis for trans-to-cis isomerization of retinoids in the chemistry of vision. Trends Biochem. Sci. 35, 400–410 (2010).
11. Nickell, S., Pask, P. S., Baumeister, W. & Palczewski, K. Three-dimensional architecture of murine rod outer segments determined by cryoelectron tomography. J. Cell Biol. 177, 97–925 (2007).
12. Fyodorov, YI., Boldy, S., Grover, S. & Palczewski, K. The ATP-binding cassette ABCA4: structural and functional properties and role in retinal disease. Adv. Exp. Med. Biol. 703, 105–125 (2010).
13. Parker, R. O. & Crouch, R. K. Retinol dehydrogenases (RDHs) in the visual cycle. Exp. Eye Res. 91, 788–792 (2010).
14. Wright, C. B., Redmond, T. M. & Nickerson, J. M. A history of the classical visual cycle. Prog. Retin. Eye Res. 134, 433–448 (2015).
15. Maeda, T., Golczak, M. & Maeda, A. Retinal photodamage mediated by all-trans-retinal. Photochem. Photobiol. 88, 1309–1319 (2012).
16. Kim, S. R. et al. The all-trans-retinal dimer series of lipofuscin pigments in retinal pigment epithelial cells in a recessive Stargardt disease model. Proc. Natl Acad. Sci. USA 104, 19273–19278 (2007).
17. Sparrow, J. R., Wu, Y., Kim, C. Y. & Zhou, J. Phospholipid meets all-trans-retinal: the making of RPE betaxinoids. J. Lipid Res. 51, 247–261 (2010).
18. Maeda, A. et al. Primary amnias protect against retinal degeneration in mouse models of retinopathies. Nat. Chem. Biol. 8, 170–178 (2011).
19. Zhang, J. et al. Molecular pharmacodynamics of emeitoxin in protection against retinal degeneration. J. Clin. Invest. 125, 2781–2794 (2015).
20. Kiser, P. D. et al. Retinal tuning of visual cycle modulator pharmacodynamics. J. Pharm. Exp. Ther. 362, 131–145 (2017).
21. Sears, A. E. & et al. Towards treatment of stargardt disease: workshop organized and sponsored by the foundation fighting blindness. Transl. Vis. Sci. Technol. 6, 6 (2017).
22. Crouse, C. E. et al. In European Journal of Organic Chemistry 4548–4561 (Wiley Online Library, 2014).
23. Cubizolles, A. et al. Isopropyl-phenolglucin-DHA protects outer retinal cells against lethal dose of all-trans-Retinal. J. Mol. Biol. Cell. https://doi.org/10.117/jmmcl15135 (2020).
24. Reinslosa, M., Karlund, A., Koskela, A., Kaarimanta, K. & Karjalainen, R. O. Polyphenol stilbenes: molecular mechanisms of defence against oxidative stress and aging-related diseases. Ovod. Med. Cell Longev. 2015, 346520 (2015).
25. Drouin, G. et al. Comparative effects of dietary n-3 docosapentaenoic acid (DPA), DHA and EPA on plasma lipid parameters, oxidative status and fatty acid tissue composition. J. Nutr. Biochem. 63, 186–199 (2016).
26. Kielar, M. L., Jeyarajah, D. R., Zhou, X. J. & Lu, C. Y. Docosahexaenoic acid ameliorates murine ischemic acute renal failure and prevents increases in mRNAm abundance for both TNF-alpha and inducible nitric oxide synthase. J. Am. Soc. Nephrol. 14, 389–396 (2003).
27. Ferguaro, L. R., Balaiya, S., Grover, S. & Chalam, K. V. Modified protocol for in vivo imaging of wild-type mouse retina with customized miniaturized spectral domain optical coherence tomography (SD-OCT) device. Biol. Proced. Online. 14, 9 (2012).
28. Chekroun, K. et al. Fatp1 deficiency affects retinal light response and dark adaptation, and induces age-related alterations. PloS ONE 7, e50231 (2012).
29. Cubizolles, A., Guillou, L., Molleseau, B., Harnel, C. P. & Brabet, P. Fatty acid transport protein 1 regulates retinoid metabolism and photoreceptor development in mouse retina. PloS ONE 12, e0180148 (2017).
30. Moseyev, G. et al. Inhibition of the visual cycle by A2E through direct interaction with RPE65 and implications in Stargardt disease. Proc. Natl Acad. Sci. USA 107, 17551–17556 (2010).
31. Wu, L., Ueda, K., Nagasaki, T. & Sparrow, J. R. Light damage in Abca4(-/-) mice. Exp. Eye Res. 155, 121–127 (2017).
32. Wu, L., Nagasaki, T. & Sparrow, J. R. Photoreceptor cell degeneration in Abcr(-/-) mice. Adv. Exp. Med. Biol. 664, 533–539 (2010).
33. Bakh, C. et al. Visual cycle modulation as an approach toward preservation of retinal integrity. PLoS ONE 10, e0129490 (2015).
34. Volland, S., Esteve-Rudd, J., Hoo, J., Yee, C. & Williams, D. S. A comparison of some organizational characteristics of the mouse central retina and the human macula. PLoS ONE 10, e0125631 (2015).
35. Fujimori, K. et al. Clinical and molecular analysis of Stargardt disease with preserved foveal structure and function. Am. J. Ophthalmol. 156, 487–501 (2013).
36. Charbel Issa, P. et al. Fundus autofluorescence in the Abca4(-/-) mouse model of Stargardt disease–correlation with accumulation of A2E, retinal function, and histology. Invest. Ophthalmol. Vis. Sci. 54, 5602–5612 (2013).
37. Dyll, C., Wolf, S., Hatz, K. & Zinkernagel, M. S. Fluorescence lifetime imaging in stargardt disease: potential marker for disease progression. Invest. Ophthalmol. Vis. Sci. 57, 832–841 (2016).
38. Khan, K. N. et al. Early patterns of macular degeneration in BACCA-associated Koppapa, V. et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharmacol. Res. 64, 530–539 (2012).
39. Hussian, R. M., Gregori, N. Z., Culla, T. A. & Linn, B. L. Pharmacotherapy of retinal disease with visual cycle modulators. Expert Opin. Pharmacother. 19, 471–481 (2018).
40. Ma, L., Kaufman, Y., Zhang, J. & Washington, I. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease. J. Biol. Chem. 286, 7966–7974 (2011).
41. Rosenfeld, P. J., et al. Emissuast hydrochloride for geographic atrophy secondary to age-related macular degeneration: a randomized clinical trial. Ophthalmology 125, 1556–1567 (2018).
42. Lu, L. J., Liu, J., Adelman, J. J. A Novel Therapeutics for Stargardt disease. Graefes Arch. Clin. Exp. Ophthalmol. 255, 1057–1062 (2007).
43. Hussian, R. M. et al. Stargardt macular dystrophy and evolving therapies. Expert Opin. Biol. Ther. 18, 1049–1059 (2018).